The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
From the Reiner/Martin interview:
Dr David Martin 33:24
Oh it does. The 5th of June 2008, which is an important date because it is actually around the time when DARPA the Defence Advanced Research Programme in the United States actively took an interest in Coronavirus as a biological weapon. June 5 2008 Ablynx, which as you know is now part of Sanofi, filed a series of patents that specifically targeted what we’ve been told is the novel feature of the SARS CoV 2 virus. And you heard what I just said, this is the 5th of June 2008.
Reiner Fuellmich 34:09
They found what?
Dr David Martin 34:10
Specifically they targeted what was called the poly basic cleavage site for SARS Cov, the novel spike protein and the ACE2 receptor binding domain which is allegedly novel to SARS CoV 2, and all of that was patented on the 5th of June 2008. And those patents in sequence were issued between November 24th of 2015, which was US Patent 9193780. So that one came out after the gain of function moratorium.
Sources:
https://patents.google.com/patent/US9193780B2,
https://patents.justia.com/patent/7220852,
Local copy.
Patent.
https://www.covidtruths.co.uk/2021/07/reiner-fuellmich-interviews-dr-david-martin-cdc-patent-fraud/.
Blog, Video, Expert.
Includes transcript.
https://www.m-cam.com/wp-content/uploads/2020/04/20200403_SARS_CoV_Patent_Corpus_Lit_Review.pdf.
Expert, PDF.
See also, on this site: